Synlogic names new CEO
This article was originally published in Scrip
Executive Summary
Synlogic, a biotechnology company focused on the development of therapeutic synthetic life, has named Dr Jose-Carlos (JC) Gutiérrez-Ramos president and CEO. Dr Gutiérrez-Ramos brings more than 20 years of experience in drug discovery and development leadership spanning the pharmaceutical and biotechnology industries as well as academia. He joins Synlogic from Pfizer where he was group senior vice-president and global head of BioTherapeutics R&D. In that role, he held responsibility for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in rare disease discovery and development, and founded the Centers for Therapeutic Innovation.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.